文献速递临床生化质量管理与危急值

Theranos能否从灰烬中重生?

Can Theranos resurrect from its ashes?
PubMed 文献 · Clin Chem Lab Med · 2025-07-18

2015年前后其商业行为和技术受审视,被揭露误导投资者、医生和患者,实际使用传统临床化学分析仪;其领导人正服刑,今年宣布与Theranos有关人员正启动新公司,目标部分重叠,本文对此新进展发表评论。

要点

  • Theranos未公开技术细节且未独立评估,却宣称革新临床化学检测。
  • 2015年前后其被揭露误导投资者、医生和患者,实际使用传统分析仪。
  • 与Theranos有关人员正启动新公司,目标部分重叠,本文评论新进展。

核心结论

  • Theranos未公开技术且未独立评估,最终被揭露误导投资者、医生和患者,其领导人正服刑。
  • 与Theranos有关人员正启动新公司,目标部分重叠,本文希望过往教训指导新领导者。
  • 文中提及该领域一些新进展可能构成 formidable 竞争。

研究设计与样本

  • 本文为评论文章,评论与Theranos有关人员启动新公司的新进展。

主要发现

  • Theranos在2010年代承诺以指尖采血微量样本和药房等传统实验室外检测革新临床化学。
  • 2015年前后其商业行为和技术受审视,被揭露误导投资者、医生和患者,实际使用传统临床化学分析仪。
  • Theranos领导人现正服刑;今年宣布与Theranos有关人员正启动新公司,目标部分重叠。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Theranos was a biotechnology company which, in the 2010s, promised to revolutionize traditional clinical chemistry testing by using novel technology, microvolumes of blood obtained by finger pricks, and performance of tests outside traditional clinical chemistry laboratories, such as in pharmacies. Theranos did not publish any details of their technology, nor sought to evaluate it independently. Despite this, it attracted millions of dollars of investments, and at a point, its market valuation reached $9 billion. Around 2015 the Theranos business practices and technology were scrutinized and it was revealed that they misled investors, doctors, and patients by falsely claiming of using their own technology, when in fact, they were using traditional clinical chemistry analyzers. The leaders of Theranos are now serving prison time. This year it was announced that a new effort is underway, by people who are related to Theranos, to start a new company, with objectives that partially overlap with those of the old company. Here, we comment on these new developments, with the hope that the lessons learned from the past will guide the new leaders to find success while mentioning that some new developments in the field will likely pose formidable competition.

来源:Clin Chem Lab Med,查看原文。版权归原作者所有。

引用

  1. Chatanaka MK, Diamandis EP, Plebani M, et al. Can Theranos resurrect from its ashes? Clin Chem Lab Med. 2025. PMID: 40670283. doi:10.1515/cclm-2025-0651

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。